Paclitaxel
- Generic Name
- Paclitaxel
- Brand Names
- Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin
- Drug Type
- Small Molecule
- Chemical Formula
- C47H51NO14
- CAS Number
- 33069-62-4
- Unique Ingredient Identifier
- P88XT4IS4D
- Background
Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.
- Indication
Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer
- Associated Therapies
- -
R101933 Combined With Chemotherapy in Treating Patients With Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-07-18
- Target Recruit Count
- 35
- Registration Number
- NCT00028873
- Locations
- 🇫🇷
CRLCC Nantes - Atlantique, Nantes-Saint Herblain, France
🇧🇪Institut Jules Bordet, Brussels, Belgium
Chemotherapy, Tirapazamine, and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2009-02-09
- Lead Sponsor
- California Cancer Consortium
- Target Recruit Count
- 30
- Registration Number
- NCT00033410
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸University of California Davis Cancer Center, Sacramento, California, United States
Combination Chemotherapy Combined With Radiation Therapy in Treating Patients Who Have Stage II or Stage III Cancer of the Esophagus
- Conditions
- Locations
- 🇫🇷
Centre Jean Bernard, Le Mans, France
🇫🇷Clinique Saint - Jean, Cagne-sur-Mer, France
🇫🇷Hopital Andre Mignot, Le Chesnay, France
Adjuvant Stage 2-3A Breast Cancer With Positive Lymph Nodes
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-10-02
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 16
- Registration Number
- NCT00007904
- Locations
- 🇺🇸
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸UH-LUICC, Mentor, Ohio, United States
🇺🇸UH-Chagrin Highlands, Orange Village, Ohio, United States
Paclitaxel in Treating Patients With Refractory or Recurrent Endometrial Cancer
- Conditions
- Locations
- 🇦🇹
Allgemeines Krankenhaus der Stadt Wien, Vienna, Austria
🇮🇹Ospedale Mauriziano Umberto I, Torino, Italy
🇬🇧Queen Elizabeth Hospital, Gateshead, England, United Kingdom
Doxorubicin and Cisplatin With or Without Paclitaxel in Treating Patients With Locally Advanced, Metastatic, and/or Relapsed Endometrial Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-09-24
- Target Recruit Count
- 141
- Registration Number
- NCT00052312
- Locations
- 🇧🇪
Universitair Ziekenhuis Antwerpen, Edegem, Belgium
🇪🇸Hospital Universitario 12 de Octubre, Madrid, Spain
🇪🇸Instituto Valenciano De Oncologia, Valencia, Spain
Paclitaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Cancer of the Vulva
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-09-24
- Target Recruit Count
- 31
- Registration Number
- NCT00014599
- Locations
- 🇳🇱
University Medical Center Nijmegen, Nijmegen, Netherlands
🇮🇹Ospedale di Circolo e Fondazione Macchi, Varese, Italy
🇮🇹Ospedale Mauriziano Umberto I, Torino, Italy
Chemotherapy Plus Radiation Therapy With or Without Amifostine in Treating Patients With Locally Advanced Cancer of the Nasopharynx
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-09-24
- Target Recruit Count
- 5
- Registration Number
- NCT00025298
- Locations
- 🇮🇹
Ospedale Santa Croce, Cuneo, Italy
🇧🇪U.Z. Gasthuisberg, Leuven, Belgium
🇮🇹Istituto Nazionale per lo Studio e la Cura dei Tumori, Naples, Italy
Capecitabine and Paclitaxel in Treating Patients With Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-05-15
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 34
- Registration Number
- NCT00031876
- Locations
- 🇨🇭
Inselspital, Bern, Bern, Switzerland
🇨🇭UniversitaetsSpital, Zurich, Switzerland
Monoclonal Antibody Plus Chemotherapy in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-03-23
- Target Recruit Count
- 55
- Registration Number
- NCT00019812
- Locations
- 🇺🇸
Mary Babb Randolph Center, Morgantown, West Virginia, United States
🇺🇸Holy Cross Hospital, Fort Lauderdale, Florida, United States
🇺🇸Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.